Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/180720
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMaristany Bosch, Marta-
dc.contributor.authorCuervo Requena, Guillermo-
dc.contributor.authorMatas Martín, Elisabet-
dc.contributor.authorVeciana de las Heras, Misericordia-
dc.contributor.authorPedro Pérez, Jordi-
dc.contributor.authorMartínez Yélamos, Sergio-
dc.contributor.authorSabé Fernández, Nuria-
dc.date.accessioned2021-10-21T12:52:50Z-
dc.date.available2021-10-21T12:52:50Z-
dc.date.issued2021-01-01-
dc.identifier.issn2467-981X-
dc.identifier.urihttp://hdl.handle.net/2445/180720-
dc.description.abstractIntroduction: Although pentavalent antimonials are no longer considered the first-line therapy for visceral leishmaniasis in the developed world, they are still used in certain geographical areas and in refractory cases. These drugs have a great number of adverse effects; however, neurological toxicity has been rarely reported. Case report: We present a 56-year-old woman who required long-term treatment with antimonial drugs due to refractory visceral leishmaniasis and presented clinically with tremor of extremities, myoclonus, gait disturbances and epileptic seizures. The EEG showed increased beta rhythms and generalized epileptogenic activity. She had a slow but favorable response after the withdrawal of antimonials and the initiation of anticonvulsant therapy. Conclusion: Severe but reversible neurological toxicity is a rare adverse effect of prolonged antimonial treatment. More EEG record data are needed to support the suspicion of a possible increase of beta rhythms in this situation. (C) 2021 International Federation of Clinical Neurophysiology. Published by Elsevier B.V.-
dc.format.extent4 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherElsevier BV-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.cnp.2021.03.008-
dc.relation.ispartofClinical Neurophysiology Practice, 2021, vol. 6, p. 164-167-
dc.relation.urihttps://doi.org/10.1016/j.cnp.2021.03.008-
dc.rightscc by-nc-nd (c) Maristany Bosch, Marta et al, 2021-
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.subject.classificationLeishmaniosi-
dc.subject.classificationTerapèutica-
dc.subject.classificationToxicitat dels medicaments-
dc.subject.otherLeishmaniasis-
dc.subject.otherTherapeutics-
dc.subject.otherDrug toxicity-
dc.titleNeurological toxicity due to antimonial treatment for refractory visceral leishmaniasis-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2021-10-21T08:06:48Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
1-s2.0-S2467981X21000214-main.pdf1.54 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons